Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…Abstract Number: 0039 • ACR Convergence 2020
Identification of a Regulatory Pathway Governing Expression of TRAF1 via a JIA-associated Non-coding Variant
Background/Purpose: Over the past decade, genome-wide association studies (GWAS) have identified TRAF1/C5 locus as a risk locus for rheumatoid diseases including RA and JIA(Plenge, Seielstad…Abstract Number: 0718 • ACR Convergence 2020
Obesity Impairs Achievement of Clinical Inactive Disease (CID) in Patients with Juvenile Idiopathic Arthritis (JIA) Treated with TNF Inhibitors
Background/Purpose: to assess prevalence and disease features associated with obesity in juvenile idiopathic arthritis (JIA) and to evaluate the impact of obesity on the achievement…Abstract Number: 1152 • ACR Convergence 2020
IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis?
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with prominent innate immune activity. Disease presentation and flares could largely mimic infections with fever…Abstract Number: 1985 • ACR Convergence 2020
Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
Background/Purpose: In the last years, the interest in the assessment of parent- and child-reported outcomes (PCROs) in paediatric rheumatic diseases is gaining increasing importance. These…Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…Abstract Number: 0720 • ACR Convergence 2020
Long Term Efficacy and Safety of Triamcinolone Hexacetonide versus Triamcinolone Acetonide Intraarticular Injection for Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide…Abstract Number: 1153 • ACR Convergence 2020
Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry
Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes. There may…Abstract Number: 0164 • ACR Convergence 2020
What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The childhood inflammatory disorder systemic juvenile idiopathic arthritis (SJIA) has historically had several names, including Still’s disease and systemic juvenile rheumatoid arthritis. While its…Abstract Number: 0722 • ACR Convergence 2020
Evaluation of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis
Background/Purpose: Biological treatment (BT) has changed the perspectives of Juvenile Idiopathic Arthritis (JIA) patients, but it remains unclear when and how to taper or to withdraw…Abstract Number: 1154 • ACR Convergence 2020
Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Canakinumab is a human anti-IL1β blocking agent that effectively neutralizes IL1β mediated signaling and is used to treat diseases such as systemic juvenile idiopathic…Abstract Number: 2788 • 2013 ACR/ARHP Annual Meeting
Reliability and Responsivenss Of The Standardized Universal Pain Evaluations For Rheumatology Providers For Children and Youth (SUPER-KIDZ)
Background/Purpose: Pain is the most common symptom in children and youth with juvenile idiopathic arthritis (JIA), however, currently there is no comprehensive validated pain measure…
- « Previous Page
- 1
- …
- 18
- 19
- 20